Communiqués Seelos Therapeutics, Inc.

Actions

SEELQ

US81577F4063

Recherche biotechnologique et médicale

Temps Différé OTC Markets Autres places de cotation 18:25:32 01/06/2026			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	+9 900,00 %		-.--%	-

21/10/25	GLD Partners, LP finalise l'acquisition de certains actifs de Seelos Therapeutics, Inc.	CI
30/04/25	Requête en conversion ou rejet de la procédure déposée par Seelos Therapeutics, Inc.	CI

Communiqués

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR
07/10/24	Seelos Therapeutics : Material Event Form 8 K	PU
26/09/24	Seelos Therapeutics : Announces Postponement of its Annual Meeting of Stockholders Form 8 K	PU
26/09/24	Seelos Announces Postponement of its Annual Meeting of Stockholders	PR
25/09/24	Seelos Therapeutics Announces 1-for-16 Reverse Stock Split	PR
24/09/24	Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD	PR
15/08/24	Seelos: Q2 Earnings Snapshot	AQ
17/05/24	Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	PR
14/05/24	Seelos Therapeutics Announces 1-for-8 Reverse Stock Split	PR
14/05/24	Seelos: Q1 Earnings Snapshot	AQ
29/04/24	Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations	PR
19/03/24	Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)	PR
29/01/24	Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	AQ
26/01/24	Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	PR
23/01/24	Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration	AQ
22/01/24	Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	PR
03/01/24	Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote 'FOR' All Proxy Proposals at the Special Meeting to be held on January 10, 2024	AQ
02/01/24	Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024	PR
22/12/23	Seelos Therapeutics, Inc. Releases Letter to its Stockholders	PR
28/11/23	Seelos Therapeutics Announces the Selection of SLS-002 for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder	AQ
27/11/23	Seelos Therapeutics Announces 1-for-30 Reverse Stock Split	AQ